TY  - JOUR
A1  - Sardanelli, Francesco
A1  - Aase, Hildegunn S.
A1  - Álvarez, Marina
A1  - Azavedo, Edward
A1  - Baarslag, Henk J.
A1  - Balleyguier, Corinne
A1  - Baltzer, Pascal Andreas Thomas
A1  - Beslagic, Vanesa
A1  - Bick, Ulrich
A1  - Bogdanovic-Stojanovic, Dragana
A1  - Briediene, Ruta
A1  - Brkljacic, Boris
A1  - Camps Herrero, Julia
A1  - Colin, Catherine
A1  - Cornford, Eleanor
A1  - Danes, Jan
A1  - Geer, Gerard de
A1  - Esen, Gul
A1  - Evans, Andrew
A1  - Fuchsjäger, Michael H.
A1  - Gilbert, Fiona J.
A1  - Graf, Oswald
A1  - Hargaden, Gormlaith
A1  - Helbich, Thomas H.
A1  - Heywang-Köbrunner, Sylvia H.
A1  - Ivanov, Valentin
A1  - Jónsson, Ásbjörn
A1  - Kuhl, Christiane Katharina
A1  - Lisencu, Eugenia C.
A1  - Luczynska, Elzbieta
A1  - Mann, Ritse M.
A1  - Marques, Jose C.
A1  - Martincich, Laura
A1  - Mortier, Margarete
A1  - Müller-Schimpfle, Markus
A1  - Ormandi, Katalin
A1  - Panizza, Pietro
A1  - Pediconi, Federica
A1  - Pijnappel, Ruud M.
A1  - Pinker, Katja
A1  - Rissanen, Tarja
A1  - Rotaru, Natalia
A1  - Saguatti, Gianni
A1  - Sella, Tamar
A1  - Slobodníková, Jana
A1  - Talk, Maret
A1  - Taourel, Patrice
A1  - Trimboli, Rubina Manuela
A1  - Vejborg, Ilse
A1  - Vourtsis, Athina
A1  - Forrai, Gabor
T1  - Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey
T2  - European radiology
N2  - EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40 % for women aged 50–69 years taking up the invitation while the probability of false-positive needle biopsy is <1 % per round and overdiagnosis is only 1–10 % for a 20-year screening. Mortality reduction was also observed for the age groups 40–49 years and 70–74 years, although with “limited evidence”. Thus, we firstly recommend biennial screening mammography for average-risk women aged 50–69 years; extension up to 73 or 75 years, biennially, is a second priority, from 40–45 to 49 years, annually, a third priority. Screening with thermography or other optical tools as alternatives to mammography is discouraged. Preference should be given to population screening programmes on a territorial basis, with double reading. Adoption of digital mammography (not film-screen or phosphor-plate computer radiography) is a priority, which also improves sensitivity in dense breasts. Radiologists qualified as screening readers should be involved in programmes. Digital breast tomosynthesis is also set to become “routine mammography” in the screening setting in the next future. Dedicated pathways for high-risk women offering breast MRI according to national or international guidelines and recommendations are encouraged.
KW  - Breast cancer
KW  - Digital breast tomosynthesis (DBT)
KW  - Digital mammography
KW  - Population-based screening
KW  - Recall rate
Y1  - 2016
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/45821
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-458210
SN  - 1432-1084
SN  - 1613-3757
SN  - 0938-7994
SN  - 1613-3749
N1  - Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
VL  - 27
IS  - 7
SP  - 2737
EP  - 2743
PB  - Springer
CY  - Berlin ; Heidelberg
ER  -